Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Authorization Safety Study on Assessment of Effectiveness of Additional Risk Minimization Measures Related to ARAVA (Leflunomide) in Saudi Arabia

Next Previous
Trial Profile

Post Authorization Safety Study on Assessment of Effectiveness of Additional Risk Minimization Measures Related to ARAVA (Leflunomide) in Saudi Arabia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leflunomide (Primary)
  • Indications Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms ARAVA PASS
  • Sponsors Sanofi

Most Recent Events

  • 11 Jun 2026 Status changed from active, no longer recruiting to completed.
  • 28 Apr 2026 Planned End Date changed from 31 Mar 2026 to 31 May 2026.
  • 28 Apr 2026 Planned primary completion date changed from 31 Mar 2026 to 31 May 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top